Shares of Gracell Biotechnologies GRCL have surged 62.3% in the one-week period compared with the industry’s breakeven growth. Zacks Investment Research Image Source: Zacks Investment Research The ...
SAN DIEGO, Calif. and SUZHOU and SHANGHAI, China, Aug. 7, 2023 /PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", Nasdaq: GRCL), a global clinical-stage biopharmaceutical ...
Novel, proprietary technology designed to strengthen the functionality of CAR-T cells against solid tumors SMART CAR-T cells demonstrated resistance to immunosuppressive tumor microenvironment (TME) ...
AstraZeneca will acquire Chinese cell therapy maker Gracell for up to $1.2 billion, representing an 86% premium to the company’s pre-announcement share price The U.S. FDA announced an investigation ...
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca has entered into a definitive agreement to acquire Gracell Biotechnologies Inc. (Gracell, NASDAQ: GRCL), a global clinical-stage biopharmaceutical ...
Turning a patient’s cells into targeted cancer fighters presents manufacturing challenges that big pharmaceutical companies and upstart biotechs are trying to address. The cell therapy field is also ...
SAN DIEGO and SUZHOU, China and SHANGHAI, China, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (GRCL), a global clinical-stage biopharmaceutical company dedicated to developing ...
SAN DIEGO and SUZHOU, China and SHANGHAI, China, March 13, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell” or the “Company”), a global clinical-stage biopharmaceutical ...
Oversubscribed transaction led by Vivo Capital and joined by leading healthcare investors including Adage Capital Partners LP, Exome Asset Management, Janus Henderson Investors, Logos Capital, OrbiMed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results